medicare physician fee schedule Archives

TAG:

medicare physician fee schedule

Proposed Medicare 2021 PFS Cuts Pathology Fees by 9%

By Robert Michel | From the Volume XXVII, No. 12 – August 24, 2020 Issue

IF THE PROPOSED MEDICARE 2012 PHYSICIAN FEE SCHEDULE (PFS) RULE—published by the Centers for Medicare and Medicaid Services (CMS) on Aug. 4—takes effect as currently written, pathology professional fees will be cut by 9%, effective Jan. 1, 2021. This was not…

CMS Adjustments for Medicare Fee Schedule Might Be Too Late

By Mary Van Doren | From the Volume XXV No. 16 – November 13, 2018 Issue

This is a summary of two articles in the Nov. 13, 2018 issue of THE DARK REPORT. The complete articles are available only to paid members of the Dark Intelligence Group. CEO SUMMARY: On Nov. 2, the federal Centers for Medicare and Medicaid Services released its Physician Fee S…

NILA, ACLA Respond to CMS 2019 Final Lab Rule

By Joseph Burns | From the Volume XXV No. 16 – November 13, 2018 Issue

CEO SUMMARY: On Nov. 2, the federal Centers for Medicare and Medicaid Services released its Physician Fee Schedule for 2019. It says it will expand the number of labs from which it collects data about the lab test prices paid by private health insurers. While some labs may welcome these c…

CMS physician fee schedule: Will hospital labs be excluded again from PAMA price reporting?

By R. Lewis Dark | From the Volume XXV No. 11 – July 30, 2018 Issue

CEO SUMMARY: Publication of the draft CMS Physician Fee Schedule on July 12 brought unwelcome news for the clinical lab industry, at least as it pertains to that perennial question: Should hospital lab outreach data be included in a PAMA market study? The federal Centers for Medicare and …

CMS Shows Its Hand in New Draft Rules for 2019

By Joseph Burns | From the Volume XXV No. 11 – July 30, 2018 Issue

CEO SUMMARY: Publication of the draft Medicare Physician Fee Schedule on July 12 brought unwelcome news for the clinical lab industry, at least as it pertains to whether hospital lab outreach data should be included in the PAMA market study that the federal Centers for Medicare and Medica…

Protecting Access to Medicare Act of 2014 Could Harm Independent Community Labs

By Mary Van Doren | From the Volume XXII No. 3 – February 17, 2015 Issue

In the Protecting Access to Medicare Act of 2014 (PAMA), the Center for Medicare and Medicaid Services (CMA) is directed to collect market price data and use the data to establish prices for the Medicare Part B Clinical Laborato…

ACLA, CAP Comment on Final 2014 Medicare Rules

By Joseph Burns | From the Volume XX, No. 16 – December 2, 2013 Issue

CEO SUMMARY: On November 27, as the nation prepared for the Thanksgiving holiday, the federal Centers for Medicare & Medicaid Services (CMS) announced the long-awaited final rules for 2014. Early analysis of the 1,300 pages of rules CMS released indicates that the agency moderated one…

Medicare Price Cuts Drive Labs to Sell or File BK

By Robert Michel | From the Volume XX No. 15 – November 11, 2013 Issue

CEO SUMMARY: Professional investors are smart with their money. Thus, it is no surprise that clinical lab and pathology companies owned by private equity firms are the first to be sold or closed. These investors are acting in response to the cumulative negative financial impact of recent …

Price Cuts, Long Delays in Payment Are Expected

By Joseph Burns | From the Volume XIX No. 18 – December 31, 2012 Issue

CEO SUMMARY: In addition to a steep cut in the 88305 CPT code, anatomic pathology laboratories can expect cuts in the payment from Medicare for molecular and prostate biopsy testing. Two national experts in lab billing and reimbursement warn labs to expect confusion in how both public and…

RDX Alters Business Plan Due to Lab Market Changes

By Joseph Burns | From the Volume XIX No. 17 – December 10, 2012 Issue

CEO SUMMARY: Executives at Regional Diagnostic Laboratories (RDX) made a splash last May when they announced the new company’s plans to acquire hospital laboratory outreach programs, backed by a capital commitment of $250 million. Now, in recognition of swift changes in the lab test mar…

Volume XXXI, No. 12 – September 3, 2024

This special intelligence briefing—presented in three parts—identifies the factors retarding a faster adoption of digital pathology. Also, how to protect your lab’s proprietary LDTs and assess the financial impact of compliance.

See the full table of contents

How Much Laboratory Business Intelligence Have You Missed?

Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!

Need A Group Membership? Company Discounts are Available!

Sign up for TDR Insider

Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.

Topics

Visit The Dark Library

TAG:

medicare physician fee schedule

CURRENT ISSUE

How Much Laboratory Business Intelligence Have You Missed?

Sign up for TDR Insider

Topics